Vanguard S&P Mid-Cap 400 Growth ETFIVOG

Vanguard’s IVOG is a mid-cap growth ETF that tracks the S&P Mid-Cap 400 Growth Index, a benchmark designed to capture the upper-middle class of US equities: companies that are too large for small-cap indexes but still too young for the S&P 500. The fund’s mandate is unashamedly passive-it exists to deliver the index’s return, minus a 0.07% annual fee, not to beat it. That fee is 83% lower than the industry average, a figure Vanguard wields like a scalpel, but it’s still a fee that compounds over decades like a silent tenant in your portfolio (source: Vanguard, https://investor.vanguard.com/investment-products/etfs).

The fund’s top holdings are a who’s who of mid-cap growth: names like Pool Corporation, Tyler Technologies, and Bio-Techne dominate the top ten, which together account for roughly a fifth of the basket. The index’s concentration rules mean the fund’s fate is tied to a handful of stocks rather than the broad mid-cap universe, a feature that can amplify gains-or losses-when those names stumble. The fund’s expense ratio is low, but the real cost is the opportunity cost of not owning the index itself, which you can’t buy at your local brokerage unless you’re willing to replicate it manually (source: Nasdaq, https://www.nasdaq.com/market-activity/etf/ivog).

Vanguard’s product pages promise a “Buy & sell page” that lets users access all the ETFs their account can hold, but the IVOG page itself is a data desert. The SEC EDGAR filing for IVOG (ticker: IVOG) is a sparse document, offering little beyond the fund’s mandate, fee structure, and index tracking method. The filing does not parse earnings, revenue, or cash flow for the underlying holdings, because it is not required to. The fund’s AUM figure is not disclosed in the evidence, but Vanguard’s average ETF expense ratio of 0.07% suggests the fund is part of a low-cost herd, not a standout (source: SEC, https://www.sec.gov/edgar/search/#/q=IVOG).

Liquidity for IVOG is decent but not spectacular. The fund trades on Nasdaq, where it settles like any other ETF, but the volume data is not supplied in the evidence. The fund’s tracking method is full replication, meaning it holds every stock in the S&P Mid-Cap 400 Growth Index, which is both a strength (no sampling error) and a weakness (no tax-loss harvesting tricks for the wrapper). The fund’s prospectus is available on Vanguard’s site, but the evidence does not supply a direct link to the IVOG prospectus-only the general ETF product page, which is the financial equivalent of being handed a menu when you asked for the chef’s special (source: Vanguard, https://investor.vanguard.com/investment-products).

The fund’s marketing leans into “high-quality, low-cost” ETFs, but IVOG is a textbook case of the wrapper doing the heavy lifting while the basket does the real work. The fund’s expense ratio is low, but the marketing’s promise of “easy trades” and “one-click access” is a veneer over a mechanical process: buy the index, hold it, charge a fee, repeat. The fund’s AUM figure is not supplied, but the evidence suggests it is part of Vanguard’s low-cost herd, not a breakout star. The fund’s tracking error is not disclosed in the evidence, but full replication implies minimal tracking error-at the cost of higher transaction fees and less tax flexibility (source: FINRA, https://tools.finra.org/fund_analyzer/).